1982) and excites continuation of the complement sequence when it is a subunit of the classical C5-or the alternative C3/C5-convertase (for reviews, see Reid & Porter, 1981; Muiller-Eberhard & Schreiber, 1980) . The complement-activating activities of C3b are controlled by factor I (C3b-inactivator; KAF), factor H (PIlH; C3b-inactivator accelerator), complement receptor type one and decay accelerating factor ('DAF') (Fearon, 1980; Nicholson-Weller et al., 1981) . Factor H is a singlechain glycoprotein 'of about 160 kDa. It was first described by Nilsson & Muller-Eberhard (1965) , and its ability to act as a control protein of the complement system was first recognized by Whaley and colleagues (Whaley & Ruddy, 1976a,b; Whaley et al., 1978) . Factor H binds to C3b and prevents the interaction of C3b with factor B and C5, dislodges the Bb fragment of factor B from the active alternative-pathway C3-convertase (C3bBb) and C5-convertase (C3bBbC3b) (Weiler et al., 1976; Pangburn & Muller-Eberhard, 1978; Nagaki et al., 1978; Conrad et al., 1978) and serves as a cofactor for the cleavage of C3b to iC3b by factor I (Pangburn et al., 1977; Harrison & Lachmann, 1980) . The proteolytic cleavage of the achain of C3b by factor I destroys -most of the biological activities of C3b, e.g., the ability to form C3bBb complexes (Conrad et al., 1978) . In addition to its regulatory role, factor H binds to lymphocytes, granulocytes and monocytes by means of a receptor Lambris & Ross, 1982) . Some authors have reported that preparations of human factor H contain a partially cleaved form of the factor in which all fragments are linked by disulphide bonds (Harrison & Lachmann, 1979; Gardener et al., 1980) . This cleavage has also been shown for guinea-pig factor H (Bitter-Suermann et al., 1981) . Trypsin digestion of native factor H mimicks this cleavage and produces fragments with comparable Mr values. The trypsin-treated factor H loses its ability to interact with surface-bound C3b, whereas the cofactor activity remains unchanged or even increases (Hong et al., 1982; Sim & DiScipio, 1982) . However, the precise binding site for C3b in factor H and the mechanisms that enable the factor to perform its regulatory functions are unknown. In the present study we treated human factor H with trypsin and purified the resulting fragments. The isolated fragments were tested for C3b binding and for factor I cofactor activity. In addition, monoclonal antibodies against factor H (MAH) were used to localize the fragment carrying the C3b-binding site and the cofactor activity. The present results show that the two functionally relevant activities are localized in the same tryptic fragment of H.
Materials and methods Complement components
All complement components were prepared from fresh human plasma. C3 was purified as described by Hammer et al. (1981) and Nilsson & Muller-Eberhard (1965) . In addition, C3 was purified from residual H, C5 and IgG by using anti-(factor H, C5, IgG, IgA)-Sepharose 4B (antibodies coupled to CNBr-activated Sepharose 4B). A modified form ofthe method described by Sim & DiScipio (1982) was used for the purification of factor H. Factor H pools resulting from DEAESephadex A-50 chromatography were further purified by ion-exchange chromatography on SPSephadex C-50 (Scm x 90cm column equilibrated in 20mM-sodium phosphate/0.05% NaN3, pH 5.9), gel filtration on Sephacryl S-200 (1.6cm x 70cm column equilibrated in 10mM-sodium phosphate/150mM-NaCl buffer, pH7.3) and affinity chromatography on anti-(C3, C5, IgG, IgA)-Sepharose 4B (equilibrated in 10mM-sodium phosphate/150mM-NaCl buffer, pH7.3). Factor I was purified as described by Lambris et al. (1980) . C3b was obtained by tryptic cleavage of C3 as described by Bokisch et al. (1969) . After stopping the reaction with Dip-F (1 mM), C3b was purified by gel filtration on Sephadex G-100 (equilibrated in 10mM-sodium phosphate/lSOmM-NaCl buffer, pH 7.3). 1 25I-C3b had a specific radioactivity of (5-5.5) x 106c.p.m./yg of C3b and was prepared with Iodogen (Pierce Chemical Co., Rockford, IL, U.S.A.) by the method of Fraker & Speck (1978) with 1 mCi of Na125I (Amersham Buchler, Braunschweig, Germany)/50 ug of C3b.
Trypsin treatment of factor H and purification of factor H fragments In all experiments, factor H was digested with Tos-Phe-CH2Cl-treated trypsin (Serva, Heidelberg, Germany) at an enzyme/substrate ratio of I :100 (w/w) in 10mM-sodium phosphate/l 50mM-NaCl buffer, pH 7.3 at 37°C. The reaction was stopped by the addition of 1 mM-Dip-F (Sigma, Miinchen, Germany). Factor H trypsin-treated for 30min was used for the purification of factor H fragments. SDS (Serva) was added to a concentration of 0.02% and the mixture was adjusted to 3M by adding solid urea. Afterwards, 50% 2-mercaptoethanol (Serva, Heidelberg, Germany) was added until its concentration was 0.2% of the total and incubation was continued for 15 min at 37°C. The trypsin-treated factor H was loaded on to a column (90cm x 2.5 cm diam.) of Sephadex G-200 (equilibrated in 100mM-NH4HCO3/3M-urea/0.05% NaN3 buffer, pH 7.0). The column was run at room temperature (average flow rate 20ml/h) and fractions (3.3 ml each) were collected. The column had been calibrated previously, under the same conditions, with aldolase (158kDa), bovine serum albumin (66kDa), ovalbumin (45 kDa) and chymotrypsinogen A (25 kDa) as molecular-mass marker proteins. Binding of MAHI and C3b to the fractions was then determined by e.l.i.s.a. Each resulting pool was dialysed against 2 x 5 litres of 10mM-sodium phosphate/i 50mM-NaCl/0.05%-NaN3 buffer, pH7.3, and was passed through 6ml of MAHI-Sepharose 4B (2mg of MAHI/ml of Sepharose 4B, equilibrated in the dialysis buffer). The column was washed with 5vol. of the equilibratic1i buffer and bound protein was eluted with phosphate-buffered saline/3M-KSCN (fraction size 1 ml; average flow rate 40ml/h). Again the fractions were tested for MAHI and C3b binding. The resulting pools were dialysed against 2 x 5litres of lOmm-NH4HCO3 buffer, pH7.0, concentrated 10-fold by freeze-drying and redissolving the protein in 0.1 (original) vol.
Antibodies
Polyclonal anti-H and anti-C3 antibodies were prepared as described by Schulz et al. (1984) . Peroxidase-conjugated rabbit anti-(goat IgG) and peroxidase-conjugated rabbit antibodies to mouse IgG were purchased from E*Y Laboratories, San Marcos, CA, U.S.A., and Dako, Copenhagen, Denmark. MAH were prepared as described by Schulz et al. (1984) from ascites or culture supernatants. In addition they were purified by affinity chromatography on factor H-coated Sepharose 4B (1.6mg of factor H/ml). Bound antibodies were eluted with 3M-KSCN (MAHI, 2 and 3) or with 10mM-sodium phosphate/150mM-NaCl buffer, pH4.0 (MAH4) and dialysed against 10mM-sodium phosphate/150mM-NaCl buffer, pH7.3. The monoclonal antibody 89A 1, which recognized an unknown antigen, was prepared as described by Schulz et al. (1984) (2)- (8) were carried out at room temperature. C3b and the antibodies were diluted in phosphate-buffered saline/bovine serum albumin/ovalbumin.
Inhibition studies with monoclonal antibodies were performed as follows. Factor H-coated plates were saturated (steps 1 and 2) and preincubated with 20Oj of the monoclonal antibody for 30min. The plate was washed twice with 200j4 of phosphate-buffered saline/Tween and saturated with 20ul of phosphate-buffered saline/bovine serum albumin ovalbumin. The assay was continued as described above, starting with step (3). The interaction of factor H with C3b fixed to an e.l.i.s.a. plate was determined in a modified form of the e.l.i.s.a. described above. The plate was coated with 20ju1 of C3b (20 sg/ml) per well instead offactor H. A 2Opl portion of serially diluted factor H was offered (in step 3) and its binding to C3b was detected by a polyclonal goat anti-(factor H) antibody (lOpg/ml) (in step 5). Phosphate-buffered saline/bovine serum albumin/ovalbumin was replaced in this assay by phosphate-bufferedsaline/bovine serum albumin, pH 7.3; all other conditions and steps were as described above. Chromatography All columns and chromatographic materials were purchased from Pharmacia, Freiburg, Germany. Factor H and monoclonal antibodies were coupled to CNBr-activated Sepharose 4B as recommended by the manufacturer. SDS/polyacrylamide-gel electrophoresis and Western blotting SDS/polyacrylamide-gel electrophoresis with 5-20% or 9-20% (w/v) gradient gels was applied generally as described by Laemmli (1970 (Fig. 2a) .
Interaction of fluid-phase C3b with surface-fixed factor H The samples of factor H prepared for the e.l.i.s.a. described above were adjusted to 20pg/ml (Lowry assay; A280). E.1.i.s.a. plates were coated with 20u1 of factor H per well and serially diluted C3b was offered. C3b binding to factor H was detected with polyclonal goat anti-C3b antibody and peroxidase-labelled anti-(goat IgG) antibody. Compared with the rapidly decreasing activity in the foregoing e.l.i.s.a., C3b now bound strongly to the surface-attached trypsin-treated factor H, even when factor H was applied after 120 min of tryptic digestion (Fig. 2b ).
Purification of tryptic factor H fragments
All fractions resulting from the Sephadex G-200 purification of tryptic factor H fragments (see the Materials and methods section) (Fig. 3a) were tested in an e.l.i.s.a. with a polyclonal anti-(factor H) antibody and with MAH1, which is directed against the 38kDa fragment of factor H. The binding of MAH1 revealed two peaks corresponding to those in the C3b-binding e.l.i.s.a. (Fig. 3b) . Next, the fractions within these peaks were pooled (as indicated by horizontal bars), dialysed and were further purified by affinity chromatography with MAHI (see the Materials and methods section). All resulting pools were analysed by SDS/polyacrylamide-gel electrophoresis on 5-20% gels under non-reducing (Fig. 4a) and reducing (Fig. 4b) conditions. A comparison of the molecular masses obtained under these conditions showed that the 160kDa band corresponded to 148kDa, the 142kDa to 134kDa, the 93kDa to 88kDa, the 52kDa to 44kDa and the 38kDa to 32kDa in the reduced and non-reduced gels respectively. The molecular masses determined from the reduced gel are used below. Under the conditions described above, tryptic cleavage of factor H resulted in four bands: 142, 93, 52 and 38 kDa (track 1). Gel filtration on Sephadex G-200 separated the remaining intact factor H, the 142 kDa and the 93 kDa fragments (= pool 1; track 2) from the 52kDa and 38kDa fragments (=pool 2; track 5). Affinity chromatography on MAHISepharose 4B retained the uncleaved factor H in pool 1 (track 3) and the 38 kDa fragment in pool 2 (track 7), whereas the 142kDa and 93kDa fragments (track 4) and the 52 kDa fragment (track 6) passed through. Pool 2 showed an additional 64kDa band in the non-reduced gel (Fig. 4a , track 5) that was shown by the immunoblotting technique to be a dimer of the 38 kDa fragment and that disappeared under reducing conditions (Fig.  4b, track 5 ). [C3bl (pg/ml) The 38kDa fragment (0) (see Fig. 4 , track 7), 142/93kDa fragments (A) (see Fig. 4 , track 4) or 52kDa fragment (0) (see Fig. 4 , track 6) were attached to an e.l.i.s.a. plate. Serially diluted C3b was offered and its binding was monitored.
Monoclonal anti-(factor H) antibodies: effect on the binding offactor H to C3b and its cofactor activityfor factor I Our foregoing conclusions were confirmed by the use of four MAH (MAH1, 2, 3 and 4) . They were tested for binding to factor H fragments with the Western-blotting technique and shown to react only with the 38 kDa fragment or its degradation products, but not with the 142 kDa fragment (result not shown). The influence of MAH on the binding of C3b to factor H was then tested in an e.l.i.s.a. Compared with the buffer (Fig. 7a) , neither unrelated monoclonal antibody nor mouse IgG interfered with the binding of C3b. However MAHI, 2 and 4 strongly inhibited the interaction of C3b and factor H, although MAH3 showed only weak inhibition. In the same assay with isolated 38 kDa fragment (50g/ml, 20g1/well) used instead of intact factor H, the inhibition pattern resembled that obtained with native factor H. In fact the inhibitory effect of the MAH was even stronger (result not shown).
The influence of MAH on the cofactor activity of factor H was also tested (Fig. 7b) . Maximal cofactor activity was achieved in the controls when factor H was preincubated with buffer (track 2) or I and H or factor H fragments A Spl portion of ' 25I-C3b (105 c.p.m.) was treated for 2 h at 37°C (in 10mM-sodium phosphate/l 50mM-NaCl buffer, pH6.5, adjusted to a conductivity of 4mS) with 5Opl of factor H (lOug/ml) (4), 50g1 of 142/93kDa (6) or 501 of 38kDa (8) fragment (200pg/ml) and 5p1 of factor I (lOg/ml). Incubation of '25I-C3b with factor H (2), 142/93 kDa (5) or 38 kDa fragment (7) without factor I served as controls. Track 1 contained only '25I-C3b, and track 3 shows 125I-C3b treated with factor I. Afterwards, the samples were analysed under reducing conditions by SDS/polyacrylamide-gel electrophoresis (9-20% gradient gel) and the gel was exposed to a Kodak X-ray film for 24h. (2), unrelated monoclonal antibody (3), MAH1 (4), MAH2 (5), MAH3 (6) or MAH4 (7) (4mg/ml). Afterwards, 10,u of 125I-C3b (105 c.p.m.) and 10l of factor I (10ug/ml) were added and incubated for 2h at 37°C (in 10mM-sodium phosphate/150mM-NaCl buffer, pH 6.5, conductivity 4mS). 1251-C3b alone served as a control (1). The samples were analysed by SDS/polyacrylamide gel electrophoresis and autoradiography (see Fig. 6 ).
with the unrelated monoclonal antibody (track 3). Pretreatment of factor H with MAH3 resulted in weak inhibition of the cofactor function (track 6). Conversely, preincubation of factor H with MAHI (track 4), MAH2 (track 5) or MAH4 (track 7) led to complete inhibition of the factor I cofactor function, yielding the same pattern obtained with 125I-C3b alone (track 1). The cofactor activity was also blocked by polyclonal anti-(factor H) antiserum, but remained unaffected by mouse IgG (result not shown).
Discussion
Our conclusion from the present study is that the isolated 38 kDa tryptic fragment of factor H carries both the C3b-binding site and the cofactor function for the cleavage of fluid-phase C3b by factor I. These findings were ascertained by the use of monoclonal anti-(factor H) antibodies directed against the 38kDa fragment of factor H.
In accordance with Hong et al. (1982) and Sim & DiScipio (1982) we found that tryptic cleavage of factor H produces first disulphide-linked 38 kDa and 142 kDa fragments. Thereby the ability of factor H to interact with surface-bound C3b was lost, whereas the cofactor function remained unaffected. In contrast with the data of Sim & DiScipio (1982) , we and Hong et al. (1982) found that the 142 kDa fragment was further cleaved into 93 kDa and 52kDa fragments, whereas the 38 kDa fragment was more resistant to tryptic cleavage and only prolonged digestion finally resulted in one or two smaller fragments (14-16kDa).
The e.l.i.s.a. systems described in the present paper were designed to investigate C3b-factor H interactions independent of other structures (e.g. cell surfaces). They were rapid, reproducible and easy to handle; however, highly purified complement components and antisera were absolute requirements. It is noteworthy that a similar technology can be used for the description of C3b-properdin and C3b-factor B interactions . With these e.l.i.s.a. techniques we could demonstrate that tryptic cleavage of factor H destroyed only the ability of factor H to interact with surface-bound C3b but not its ability to bind fluid-phase C3b (Fig. 2) Fig. 7 we showed that those MAH inhibiting the binding of fluid-phase C3b to surface-bound factor H (MAHI, 2 and 4) also inhibited the cofactor function in solution, whereas MAH3 with low effect on C3b binding also left the cofactor function undisturbed. Furthermore we showed that MAHI and 2 inhibited the binding of factor H to C3b-coated red blood cells, but MAH3 did not. In addition, the epitopes recognized by MAH 1 and 2 were not accessible in preformed C3b-factor H complexes, while the determinant recognized by MAH3 remained available. These data suggest that there is only one C3b-binding site in factor H for fluid-phase and surface-bound C3b. Under such a condition, and since the trypsin-treated factor H binds differently to surface-bound C3b (Fig. 2a) and to fluid-phase C3b ( Fig. 2b ; cofactor assay), an additional difference must exist between bound and fluid-phase C3b, probably in conformation.
A critical step of the factor H-fragment purification was the reduction of the disulphide bonds in the trypsin-treated factor H without loss of activity. In 1982, DiScipio & Hugli reported that the functions of H (C3b binding, cofactor activity) are very susceptible to agents that can rupture disulphide bonds and that the integrity of the original disulphide bridges is required for a functionally active molecule. In accordance with their data we found that even under fairly mild conditions (IOmM-dithiothreitol in 0.1 M-Tris/HCl buffer, pH 8.6, 2 h at 37°C) there is a total loss of all factor H activities that are not restored by subsequent alkylation with iodacetamide. In an attempt to reduce the interchain disulphide bonds in the trypsin-treated factor H without loss of function, we found that a mixture of 0.2% 2-mercaptoethanol, 3M-urea and 0.02% SDS in 10mM-sodium phosphate/150mM-NaCl buffer, pH7.3 (incubated for 15min at 37°C) was optimal for the separation of the trypsin-generated fragments. Under these conditions only the interchain disulphide bridges were cleaved, whereas the intrachain disulphide bridges, which appear to be important for the functional activity of the molecule, seem to remain undisturbed. A decrease in the amount of one of the added reagents (SDS, urea or 2-mercaptoethanol) led to an aggregation of the trypsin-treated factor H, whereas an increase of the amount of 2-mercaptoethanol destroyed the functional activities of the isolated fragments.
Since the 38 kDa tryptic fragment of factor H was shown in the present study to carry the C3b binding site and the cofactor activity, it would be of interest now to look for functional and structural similarities between the other cofactors for factor I, the C4b-binding protein and the human erythrocyte C3b receptor, which also manifested disulphide-linked 35-38 kDa fragments after tryptic digestion (Reid & Gagnon, 1982; Sim & DiScipio, 1982) .
